You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 763 Phase 1/2 dose escalation and dose expansion study of transCon TLR7/8 agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumor malignancies: initial results from dose escalation

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
763 Phase 1/2 dose escalation and dose expansion study of transCon TLR7/8 agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumor malignancies: initial results from dose escalation
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to September 2024

AbstractFullPdf
Nov 2022274018
Dec 20229209
Jan 20235806
Feb 202368010
Mar 20235606
Apr 20235605
May 20233403
Jun 20233009
Jul 20235008
Aug 202311708
Sep 202354010
Oct 20237608
Nov 20232003
Dec 20235808
Jan 20242004
Feb 20243001
Mar 20245209
Apr 20244804
May 202442011
Jun 20242403
Jul 20243408
Aug 202438010
Sep 20244208
Total13730169